TherapeuticsMD (TXMD) Receivables - Net (2010 - 2025)

TherapeuticsMD (TXMD) has reported Receivables - Net for 16 consecutive years, with $17.2 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Receivables - Net fell 11.93% year-over-year to $17.2 million; the trailing twelve-month figure through Dec 2025 stood at $17.2 million (down 11.93% YoY), and the FY2025 full-year result was $17.2 million, down 11.93% from the prior year.
• Receivables - Net declined to $17.2 million in Q4 2025 per TXMD's latest filing, from $19.6 million in the prior quarter.
• Across five years, Receivables - Net topped out at $45.8 million in Q2 2022 and bottomed at $17.2 million in Q4 2025.
• Historically, Receivables - Net has averaged $31.3 million across 5 years, with a median of $33.6 million in 2021.
• The sharpest annual moves came in 2021 and 2022: Receivables - Net soared 83.05% in 2021, then decreased 14.02% in 2022.
• Over 5 years, Receivables - Net stood at $36.2 million in 2021, then retreated by 11.11% to $32.2 million in 2022, then slumped by 32.91% to $21.6 million in 2023, then slipped by 9.28% to $19.6 million in 2024, then retreated by 11.93% to $17.2 million in 2025.
• According to Business Quant data, Receivables - Net over the past three periods registered $17.2 million, $19.6 million, and $21.6 million for Q4 2025, Q4 2024, and Q4 2023 respectively.